Anticancer Drug Development

por Loadman, P
Publicado 2002

Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon.

por Double, J. A., Bibby, M. C., Loadman, P. M.
Publicado 1986

Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours.

por Phillips, R. M., Loadman, P. M., Cronin, B. P.
Publicado 1998

Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).

por Bibby, M. C., Double, J. A., Loadman, P. M.
Publicado 1988

Pre-clinical evaluation of a novel chloroethylating agent, Clomesone.

por Matthew, A. M., Phillips, R. M., Loadman, P. M., Bibby, M. C.
Publicado 1993

Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid).

por Bibby, M. C., Double, J. A., Phillips, R. M., Loadman, P. M.
Publicado 1987

Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.

por Bibby, M. C., Loadman, P. M., al-Ghabban, A. F., Double, J. A.
Publicado 1992

Drug delivery in a tumour cord model: a computational simulation

por Hubbard, M. E., Jove, M., Loadman, P. M., Phillips, R. M., Twelves, C. J., Smye, S. W.
Publicado 2017

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

por Rustin, G J S, Bradley, C, Galbraith, S, Stratford, M, Loadman, P, Waller, S, Bellenger, K, Gumbrell, L, Folkes, L, Halbert, G
Publicado 2003